Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Fulcrum Therapeutics (FULC) over the last 4 years, with Sep 2025 value amounting to -$0.31.
- Fulcrum Therapeutics' EPS (Weighted Average and Diluted) rose 11.43% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.21, marking a year-over-year decrease of 290.32%. This contributed to the annual value of -$0.16 for FY2024, which is 89.94% up from last year.
- Fulcrum Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.31 in Q3 2025, which was down 10.71% from -$0.28 recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.87 in Q2 2024 and a low of -$0.83 during Q2 2022.
- In the last 3 years, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.36 in 2023 and averaged -$0.24.
- In the last 5 years, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 328.95% in 2024 and then slumped by 132.18% in 2025.
- Over the past 5 years, Fulcrum Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.58 in 2021, then climbed by 18.97% to -$0.47 in 2022, then rose by 14.89% to -$0.40 in 2023, then spiked by 32.50% to -$0.27 in 2024, then climbed by 11.43% to -$0.31 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.31 for Q3 2025, versus -$0.28 for Q2 2025 and -$0.27 for Q4 2024.